PT  - JOURNAL ARTICLE
AU  - Juan Pablo Prada
AU  - Luca Estelle Maag
AU  - Laura Siegmund
AU  - Elena Bencurova
AU  - Liang Chunguang
AU  - Eleni Koutsilieri
AU  - Thomas Dandekar
AU  - Carsten Scheller
TI  - Estimation of R0 for the spread of SARS-CoV-2 in Germany from Excess Mortality
AID  - 10.1101/2021.11.14.21266295
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.14.21266295
4099  - http://medrxiv.org/content/early/2021/11/15/2021.11.14.21266295.short
4100  - http://medrxiv.org/content/early/2021/11/15/2021.11.14.21266295.full
AB  - For SARS-CoV-2, R0 calculations report usually 2-3, biased by PCR testing increases. Covid-19-induced excess mortality is less biased.We used data from Robert Koch Institute on Covid incidence, deaths, and PCR tests and excess mortality to determine early, policy-free R0 estimates with a serial interval of 4.7 days.The PCR-based R0 value was 2.56 (95% CI 2.52-2.60) for Covid-19 cases and 2.03 (95%CI 1.96-2.10) for Covid-19-related deaths. As the number of PCR tests increased, R0 values were corrected accordingly, yielding 1.86 for Covid-19 cases and 1.47 for Covid-19 deaths, excess deaths were 1.34 (95% CI 1.32-1.37).R0 is much lower than previously thought. This fits the observed seasonal pattern of infection across Europe in 2020-2021, including emergence of more contagious escape variants such as delta.One-Sentence Summary Excess mortality reveals infection speed in Covid-19 is surprisingly low with seasonal infection patterns and escape variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Land of Bavaria as contribution to our DFG project 324392634-TRR 221/INF.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study contains data from incidence of Covid-19 and data of excess death from Germany, all publicly available.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://www.rki.de/DE/Home/homepage_node.html https://www.rki.de/DE/Home/homepage_node.html